4 курс / Акушерство и гинекология / Косова_А_С_Преэклампсия_современные_подходы_к_прогнозированию_и

111

S. Bezerra Maia e Holanda Moura et al. // Ultrasound Obstet Gynecol. - 2014. – Vol.44, - N.4. – P. 411–418.

100. Hairong, Xu. Role of nutrition in the risk of preeclampsia / Xu. Hairong,

B.Shatenstein, Luo Zhong-Cheng et al. // Nutrition rev. – 2009. – Vol.67, N.11. –

P.639-657.

101.Hai-Tao, Yuan. Angiogenic factors in the pathogenesis of preeclampsia / Yuan. Hai-Tao, D. Haig, A.Karumanchi // Cur Top Development Biol.–2005.–N.71.– P.297-312.

102.Hanisch, C.G. Adhesion molecules, activin and inhibin candidates for the biochemical prediction of hypertensive diseases in pregnancy? / C.G. Hanisch, K.A. Pfeiffer, H. Schlebusch, J. Schmolling // Arch.Gynecol Obstet. – 2004. – Vol.270, N.2. – P. 110-115.

103.Hayashi, M. Elevation of serum macrophage colony-stimulating factor before the clinical manifestations of preeclampsia / M. Hayashi, T. Ohkura, N. Inaba // Am J Obstet Gynecol. – 2003. – N.189. – P. 1356-1360.

104.Heyborne, K.D. Preeclampsia prevention: lessons from the low-dose aspirin therapy trials / K.D. Heyborne // Am J Obstet Gynecol. – 2000. – Vol.183, N.3. –

P.523-528.

105.Hofmeyr, G.J. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems / G.J. Hofmeyr, T.A. Lawrie, A.N. Atallach, L.Duley. - Cochrane Database Syst Rev. - 2010(8), CD001059.

106.Hofmeyr, G.J. Dietary calcium supplementation for prevention of pre-eclampsia and related problems / G.J. Hofmeyr, L. Duley, A.Atallah // BJOG. – 2007. – N.114. – P. 933 – 943.

107.Hogberg, V. The effect of smoking and hypertensive disorders on abruptio placentae / V.Hogberg, S. Rasmussen, L.M. Irgens // Acta Obstet Gynecol Scand.

– 2007. – Vol.86, N.3. – P. 304-309.

108.Hogg, B. Second-trimester plasma homocysteine levels and pregnancy-induced

hypertension, preeclampsia and intrauterine growth restriction / B.Hogg, Т. Tamura, K. Johnston et al. // Am J Obstet Gynecol.– 2000.– N.183.– P.805-809.

112

109.Hypponen, E. Vitamin D for the prevention of preeclampsia? A hypothesis / E. Hypponen // Nutrition Reviews J. – 2005. – Vol.63, N.7. – P. 225-232.

110.Imdad, A. Role of calcium supplementation during pregnancy in reducing risk of developing gestational hypertensive disorders / A. Imdad, A. Jabeen, Z.A.Bhutta // BMC Public Health. – 2011. – N.11, suppl 3. - S18.

111.Inversetti, A. Predictive biomarkers of pre-eclampsia and effectiveness of preventative interventions for the disease / A. Inversetti, M. Smid, M. Candiani et al. // Expert Opinion on Biological Therapy. - 2014. - Vol.14, - N.8. – P. 1161-

1173.

112. Kane, S.C. New directions in the prediction of pre-eclampsia / S.C. Kane, F. Da Silva Costa, S.P. Brennecke // ANZJOG Australian and New Zealand Journal of Obstetrics and Gynaecology. – 2014. – Vol.54, - N.2. – P. 101–107.

113.Kane, S.C. Contemporary clinical management of the cerebral complications of preeclampsia / S.C. Kane, A. Dennis, F. da Silva Costa et al. // Obstetrics and Gynecology International. – 2013. – Vol.2013. - Article ID 985606, 10 pages.

114.Khalil, A. First-trimester markers for the prediction of pre-eclampsia in women with a-priori high risk / A. Khalil, N.J. Cowans, K. Spenser et al. // Ultrasound Obstet Gynecol. – 2010. – Vol.35, - N.6. – P. 671–679.

115.Kilari, A. A novel molecular mechanistic hypothesis to validate the therapeutic effects of tribulus terrestris (Gokshur) to ameliorate pathophysiology and improve pregnancy and fetal outcome in preeclampsia / A. Kilari, M. Deshpande, S. Joshi // Gynecol Obstet (Sunnyvale). – 2014. – Vol.4 – N.1. – P. 1-7.

116.Kim, Shin-Young. Maternal plasma and amniotic fluid SFLT-1 and PLGF levels at the time of midtrimester amniocentesis in women who subsequently develop preeclampsia / Shin-Young Kim, Hyun-Mee Ryu, Jag-Hyng Jang // Am J Obstet Gynecol – 2006. – Vol.195, N.6, suppl 130.

117.Kliman, H.J. Placental protein13 and decidual zones of necrosis: immunologic

diversion that may by linked to pre-tclampsia / H.J. Kliman, M. Sammar, Y.I. Grimpel et al. // Reproductive Science. – 2011. –N.0. – P. 1 – 15.

118. Koga, K. Elevated serum soluble vascular endothelial growth factor receptor 1

113

(sVEGFR-1) levels in women with preeclampsia / K. Koga, Y. Osuga, O. Yoshino et al. // J Clin Endocrinol Metab. – 2003. – Vol.88, N.5. – P. 2348-2351.

119.Kopcow, H. Angiogenic factors and natural killer (NK) cells in the pathogenesis of preeclampsia / H. Kopcow, S.Karumanchi // J Reprod Immunol.–2007.–N.7–P.23- 29.

120.Kronborg, C.S. Longitudinal measurement of cytokines in preclamptic and normotensive pregnancies / C.S.Kronborg, J.G. Jedsted, E. Wittinghus et al. // Acta Obstet Gynecol Scand. – 2011. – Vol.90, N.7. – P. 791 – 796.

121.Lai, J. Maternal serum placental growth factor, pregnancy-associated plasma protein-A and free β-Human chorionic conadotrophin at 30-33 weeks in the prediction of pre-eclampsia / J. Lai, A. Pinas, L.C.Y. Poon et al. // Fetal Diagn Ther. -2013. - Vol.33, - N.3. – P. 164-172.

122.Lapaire, O. The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future

application / O. Lapaire, A. Shennan, H.Stepan // Europ J Obstet Gynecol. – 2010.

– N.151. – P. 122-129.

123. Leslie, K. Early prediction and prevention of pre-eclampsia // K. Leslie,

B.Thilaganathan, A. Papageorghiou // Best Pract Res Clin Obstet Gynaecol. – 2011. – Vol. 25, N.3. – P. 343 – 354.

124.Leung, K.Y. First-trimester ultrasound volumetry / K.Y. Leung, T. Ma, B. Lau,

G.Minchen // Expert Rev Obstet Gynecol. – 2012. – Vol.7, N.4. – P. 379 – 386.

125. Levine, R.J. Circulating angiogenic factors and the risk of preeclampsia / R.J. Levine, S.E. Maynard, C. Qian et al. // N Engl J Med. – 2004. – N.350. – P. 672-683.

126.Lim, J.H. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors / J.H. Lim, S.Y. Kim, S.Y. Park et al. // Obstet Gynecol. - 2008. – Vol.111, N.6. – P. 1403-1409.

A. MacKay, C. Berg, H.Atrash // Obstet Gynecol. – 2001. – Vol.97, N.4. – P. 533538.

132.Maynard, S. Preeclampsia and angiogenic imbalance / S.Maynard, F.H.Epstein, S.A.Karumanchi // Annu Rev Med. – 2008. – N.59 – P. 61-78.

133.Mazar, R.M. Metabolic score as a novel approach to assessng preeclampsia risk /

R.M. Mazar, S.K.Srinivas, M.D. Sammel et al. // Am J Obstet Gynecol. – 2007. - Vol.197, N4. – P. 411e1-e5.

134. Meiri, H. First trimester PP13 as a marker for prediction of pre-eclampsia /

H.Meiri, N. Chefetz, M. Sammar et al. // Biomarkers, CLI. - 2006

135.Melchiorre, K. First-trimester uterine artery Doppler indices in term and preterm pre-eclampsia / K. Melchiorre, B. Wormald, K. Leslie et al. // Ultrasound Obstet Gynecol. – 2008. – Vol.32, - N.2. – P. 133–137.

136.Mello, G. Thrombophilia is significantly associated with severe preeclampsia results of a large-scale, case-controlled study / G. Mello, E. Parretti, L. Marozio et al. // Hypertension. – 2005. – Vol. 46. – P. 1270-1274.

137.Metcalfe, A. Prediction of obstetrical risk using maternal serum markers and clinical risk factors / A. Metcalfe, S. Langlois, J. MacFarlane et al. // Prenatal Diagnosis. – 2014. – Vol.34, - N.2. – P. 172–179.

138.Metz, T.D. Preeclampsia in high risk women is characterized by risk group-

specific abnormalities in serum biomarkers / T.D. Metz, A.A. Allshouse, A.G. Euser, K.D. Heyborne // American Journal of Obstetrics & Gynecology. –

115

2014. - Vol. 211, - N.5. – P. 512.e1–512.e6.

139.Minakami, H. Gestational thrombocytopenia / H. Minakami, I. Sato // Lancet. – 2000. – N.356. – P. 1354-1355.

140.Molvarec, A. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia / A. Molvarec, A. Szarka, S. Walentin et al. // Hypertension Research. – 2010. – Vol.33. – P. 892-898.

141.Moore Simas, T.A. Angiogenic factors for the prediction of preeclampsia in high-

risk women / T.A. Moore Simas, S.L. Crawford, M.J. Solitro et al. // Am J Obstet Gynecol. – 2007. – N.197. – P. 244-248.

142. Morlin, B. Nitric oxide induces endometrial secretion at implantation time /

B.Morlin, E. Andersson, B.Bystrom // Acta Obstet Gynecol Scand. – 2005. – N.84. – P. 1029-1034.

143.Murphy, S.R. Role of endothelin in mediating soluble fms-like tyrosine kinase 1- induced hypertension in pregnant rats / S.R. Murphy, B. LaMarca, K. Cockrell,

J.Granger // Hypertension. – 2010. – N.55 – P. 394-398.

144.Myers, J.E. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study / J.E. Myers, L.C. Kenny, L.M.E. McCowan et al. // BJOG. – 2013. – Vol.120, - N.10. – P. 1215–1223.

145.Napolitano, R. Uterine artery Doppler screening for pre-eclampsia: comparison of

the lower, mean and higher first-trimester pulsatility indices / R. Napolitano,

R.Rajakulasingam, A. Memmo et al. // Ultrasound Obstet Gynecol. - 2011. – Vol. 37, - N.5. – P. 534–537.

146.National Institute for Health and Clinical Excellence. NICE clinical guideline 107. Hypertension in pregnancy. The management of hypertensive disorders during pregnancy / NICE, - 2010.

147.Nicolaides, K.H. A novel approach to first-trimester screening for early preeclampsia combining serum PP-13 and Doppler ultrasound / K.H. Nicolaides,

R.Bindra, O.M. Turan et al. // Ultrasound in Obstet Gynecol. – 2006. – Vol.27,

116

N.1. – P. 13-17.

148.North, R. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort / R. North, L. McCowan, G. Dekker et al. // BMJ. – 2011. - Vol.342. - d1875.

149.Odibo, A.O. Firsttrimester placental protein 13, PAPP-A, uterine artery Doppler

and maternal characteristics in the prediction of pre-eclampsia / A.O. Odibo,

Y.Zhong, K.R. Goetzinger et al. // Placenta. – 2011. – N.32. – P. 598 – 602.

150.Odibo, A.O. Pregnancy associated-plasma protein-A (PAPP-A) and alfafetoprotein (AFP) associated with placental abruption / A.O. Odibo // Am J Obstet Gynecol. – 2014. – Vol.211, N.2. – P. 89-90.

151.Onwudiwe, N. Prediction of pre-eclampsia by a combination of maternal history, uterine artery Doppler and mean arterial pressure / N.Onwudiwe, C.K. Yu, L.C. Poon et al. // Ultrasound Obstet Gynecol. – 2008. – Vol.32, N.7. – P. 877-883.

152.Ophir, E. Newborns of pre-eclamptic women: a biochemical difference present in utero / E. Ophir, G. Dourleshter, Y. Hirsh et al. // Acta Obstet Gynecol Scand. – 2006. – Vol.85, N.10. – P. 1172-1178.

153.Papageorghiou, A.T. Predicting and preventing pre-eclampsia—where to next? / A.T. Papageorghiou // Ultrasound Obstet Gynecol. - 2008. – Vol.31, - N.4. – P. 367–370.

154.Parra, M. Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markersof oxidative stress and endothelial dysfunction / M. Parra, R. Rodrigo, P. Barja // Am J Obstet Gynecol. – 2005. – VOL.193, N.4.

– P. 1486-1491.

155.Parra-Cordero, M. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy / M. Parra-Cordero, R. Rodrigo, P. Barja et al. // Ultrasound Obstet Gynecol. - 2013. – Vol.41, - N.5. – P. 538–544.

156.Pattison, N.S. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? / N.S. Pattison, L.W. Chamley,

M.Birdsall et al. // Am J Obstet Gynecol. – 2000. – N.183. – P. 1008-1012.

117

157.Payne, B. Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia

Integrated Estimate of RiSk) cohort, collected on admission / B. Payne,

S. Hodgson, J.A. Hutcheon et al. // BJOG. – 2013. – Vol.120, - N.1. – P. 113–118.

158.Petri, M. Pregnancy in SLE / M. Petri // Baillieres Clin Rheumatol. – 1998. - N12. – P. 151155.

159.Pilalis, A. Scrining for preeclampsia and fetal growth restriction by uterine artery

Doppler and PAPP-A at 11 – 14 weeks gestation / A. Pilalis, A.P. Souka,

P.Antsaklis et al. // Ultrasound Obstet Gynecol. – 2007. – N.29. – P. 135 – 140.

160.Pipkin, F.B. Risk factors for preeclampsia / F.B. Pipkin // N Engl J Med. - 2001. – N.344. – P. 925-926.

161.Plasencia, W. Uterine artery Doppler at 11 to 13 weeks in the prediction of preeclampsia / W.Plasencia, N. Maiz, L. Poon, H. Nicolaides // Ultrasound. Obstet. Gynecol. - 2008. - Vol.32. - P.138 – 146.

162.Poon, L.C. First-Trimesters maternal serum pregnancy-associated plasma protein-

Aand pre-eclampsia / L.C. Poon, N. Maiz, C. Valencia et al. // Ultrasaund Obstet Gynecol. – 2009. - Vol 33. - P. 23-33.

163.Poon, L.C. Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks / L.C. Poon,

V.Stratieva, S. Piras et al. // Prenat Diagn. – 2010. - Vol.30. - P. 216 - 223.

164.Prajapati, S.R. Prediction of pre-eclampsia by a combination of maternal history, uterine artery Doppler, and mean arterial pressure (A Prospective Study of 200 Cases) / S.R. Prajapati, N. Maitra // The Journal of Obstetrics and Gynecology of India. – 2013. – Vol. 63(1). – P. 32-36.

165.Rana, S. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia / S. Rana, S.A. Karumanchi, R.J. Levine // Hypertension. – 2007. – N.50. – P. 137-142.

166.Redman, C.W. Preeclampsia: an excessive maternal inflammatory response to pregnancy / C.W. Redman, G.P. Sacks, I.L.Sargent // Am J Obstet Gynecol. – 1999. – N.180. – P. 499-506.

118

167.Roberge, S. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis / S. Roberge, K. H. Nicolaides, S. Demers et al.

//Ultrasound in Obstetrics & Gynecology. - 2013. – Vol.41, – N.5. – P. 491–499.

168.Roberts, J.M. The two stage model of preeclampsia: variations on the theme / J.M. Roberts, C.A. Hubelab // Placenta. – 2009. – N.30, - P. 32-37.

169.Roberts, J.M. Vitamins C and E to prevent complications of pregnancy-associated hypertension / J.M. Roberts, L. Myatt, C.Y. Spong et al. // N Engl J Med. - 2010.

– Vol.362, N.14. – P. 1282-1291.

170.Roberts, M. Pathogenesis and genetics of pre-eclampsia / M. Roberts, D.Cooper // Lancet. – 2001. – N.357. – P. 53-56.

171.Rocha-Hernandez, J.F. Other predictive markers of pre-eclampsia / J.F. RochaHernandez, C. Zerquera-Gonzalez, M.A. Santos-Pena et al. // BMJ – 2008. – N.336 – P. 1079-1080.

172.Roes, E.M. First trimester inhibin-A concentrations and later development of preeclampsia / E.M. Roes, M. Gaytant, C. Thomas et al. // Acta Obstet Gynecol Scand. – 2004. – Vol.83, N.1. – P. 117

173.Rogers, E. Folate deficiency and plasma homocysteine during increased oxidative stress / E. Rogers, B. Shan Shen Chen, E.Chan // New Engl J Med. – 2007. – N.357. – P. 421-424.

174.Rossi, A.C. Prevention of pre-eclampsia with low-dose aspirin or vitamins C and E in women at high or low risk: a systematic review with meta-analysis / A.C.Rossi

//Eur J Obstet Gynecol Reprod Biol. – 2011. – Vol.158, N.1. – P. 9-16.

175.Ruano, R. Prevention of preeclampsia with low dose aspirin – a systematic review and meta-analysis of the main randomized controlled trials / R. Ruano, R. Fontes, M. // Zugaib Clinics. – 2005. – Vol.60, N.5. – P. 407-414.

176.Ruma, M. Maternal periodontal disease, systemic inflammation, and risk for preeclampsia / M. Ruma, K. Boggess, K. Moss et al. // Am J Obstet Gynecol. – 2008. – N.198. – P. 389-385.

177.Sanna, G. Central nervous system involvement in the antiphospholipid (Hughes) syndrome / G. Sanna, M.L. Bertolaccini, M.J. Guadrado et al. // Rheumatology. –

119

2003. – Vol.42, N.2. – P. 200-213.

178.Sawidou, M.D. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop preeclampsia / M.D. Sawidou, A.D. Hingorani, D. Tsikas et al. // Lancet. – 2003. –

N.361. – P. 1511-1517.

179. Saxena, A.R. First trimester PAPP-A levels correlate with sFlt-1 levels longitudinally in pregnant women with and without preeclampsia / A.R. Saxena, E.W. Seely, J.W. Rich-Edwards et al. //BMC Pregnancy and Childbirth. - 2013, 13:85.

180.Scazzoccio, E. Performanse of a first trimester screening of preeclampsif in a routine care low-risk setting / E. Scazzoccio, F. Figueras, F. Crispi et al. // Am J Obstet Gynecol. – 2013. – Vol.208, N.3. – P. 203e1 – 203e10.

181.Schisterman, E.F. Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial / E.F. Schisterman, R.M. Silver, L.L. Lesher et al. // The Lancet. – 2014. – Vol.384, N.9937. – P. 29-36.

182.Schoofs, K. The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction / K. Schoofs, U. Grittner, Th. Engels et al. // Journal of Perinatal Medicine. - 2014. – Vol.42, - N.1. – P. 61–68.

183.Shaarawy, M. Plasma endothelin-1 and mean arterial pressure in the prediction of pre-eclampsia / M. Shaarawy, A. Abdel-Magid // Int J Gynaecol Obstet. – 2000. – Vol.68, N.2. – P. 105-111.

184.Sibai, B. Pre-eclampsia / B. Sibai, G. Dekker, M. Kupferminc // Lancet. - 2005. – N.365. – P. 785-799.

185.Sibai, B.M. Prevention of preeclampsia. A big disappointment / B.M. Sibai // Am J Obstet Gynecol. – 1998. – N.179. – P. 1275-1278.

186.Simchen, M.J. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome / M.J. Simchen, M. Dulitzki, G. Rofe et al. // Acta Obstet Gynecol Scand. – 2011. – Vol.90, N.12. – P. 1428 – 1433.

187.Simone, N.D. Pregnancies complicated with antiphospholipid syndrome: the

120

pathogenic mechanism of antiphospholipid antibodies / N.D. Simone, M.P. Luigi, D'A. Marco et al. // Annals of the New York Academy of Sciences. – 2007. - Vol.1108. – P. 505–514.

188. Skjaerven, R. Recurrence of pre-eclampsia across generations exploring fetal and maternal genetic components in a population based cohort / R. Skjaerven, L.J. Vatten, A.J. Wilcox et al. // BMJ – 2005. – Vol.331, N.7521. – P. 877.

189.Spencer, K. First trimester maternal serum PP-13, PAPP-A and second trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia / K. Spencer, N.J. Cowans, I. Chefetz et al. // Ultrasound in Obstet Gynecol J. – 2007. – Vol.29, N.2. – P. 128-134.

190.Spencer, K. Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia / K. Spencer, N.J. Cowans, I. Chefetz et al. // Prenatal Diagnosis. – 2007. – Vol.27, N.3. – P. 258-263.

191.Spinnato, J.A. Antioxidant therapy to prevent preeclampsia: a randomized controlled trial / J.A. Spinnato, S. Freire, E. Pinto et al. // Obstet Gynecol. – 2007.

–Vol.110, N.60. – P. 1311-1318.

192.Stevens, D.U. Cardiovascular and thrombogenic risk of decidual vasculopathy in preeclampsia / D.U. Stevens, S. Al-Nasiry, M.M. Fajta, J. Bulten // Am J Obstet Gynecol. – 2014. – Vol.210, N.6. – P. 545.e1–545.e6.

193.Syngelaki, A. Body mass indexat 11 – 13 weeks gestation and pregnancy complications / A. Syngelaki, F.E. Bredaki, E. Vaikousi et al. // Fetal Diagn Ther.

–2011. – N.30. – P. 250 – 265.

194.Szarca, A. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array / A. Szarka, J. Rigó, L. Lázár et al. // BMC Immunol. – 2010, 11: 59.

195.Taylor, R.N. Longitudinal serum concentrations of placental growth factor

evidence for abnormal placental angiogenesis in pathologic pregnancies / R.N. Taylor, J. Grimwood, R.S. Taylor et al. // Am J Obstet Gynecol. – 2003. – N.188. – P. 177-182.

196. Teixeira, P.G. Placental growth factor (PlGF) is a surrogate marker in preeclamptic